QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
QQQ   323.59 (+3.01%)
AAPL   127.79 (+5.39%)
MSFT   236.94 (+1.96%)
FB   264.91 (+2.83%)
GOOGL   2,069.66 (+2.36%)
TSLA   718.43 (+6.36%)
AMZN   3,146.14 (+1.72%)
NVDA   553.67 (+0.93%)
BABA   241.69 (+1.65%)
CGC   34.73 (+6.05%)
GE   13.11 (+4.55%)
MU   94.76 (+3.53%)
NIO   49.76 (+8.69%)
AMD   86.39 (+2.22%)
T   28.09 (+0.72%)
F   11.98 (+2.39%)
ACB   11.04 (+4.94%)
DIS   194.98 (+3.14%)
BA   224.39 (+5.84%)
NFLX   550.64 (+2.19%)
BAC   35.79 (+3.11%)
Log in
NASDAQ:JAGX

Jaguar Health Stock Forecast, Price & News

$2.15
+0.05 (+2.38 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.11
Now: $2.15
$2.23
50-Day Range
$2.10
MA: $2.95
$4.00
52-Week Range
$0.19
Now: $2.15
$4.47
Volume5.09 million shs
Average Volume51.94 million shs
Market Capitalization$253.31 million
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. It operates through two reportable segments, Human Health and Animal Health. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals. Its human health product pipelines include crofelemer, which is in Phase III clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, idiopathic/functional diarrhea, and irritable bowel; and SB-300, a second-generation anti-secretory agent for various indications, including cholera. The company's animal health product candidates comprise Canalevia, an animal prescription drug product candidate intended for treatment of chemotherapy-induced diarrhea in dogs; and Equilevia, a non-prescription product for total gut health in equine athletes. In addition, its products include Neonorm Calf and Neonorm Foal. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
Jaguar Health logo

Headlines

Jaguar Health, Inc.: Jaguar Health Launches Website for Napo EU
February 23, 2021 |  finanznachrichten.de
Jaguar Health Launches Website for Napo EU
February 23, 2021 |  finance.yahoo.com
The Game Has Dramatically Changed for Jaguar Health
February 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JAGX
CUSIPN/A
Phone415-371-8300
Employees29
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$0.16 per share

Profitability

Net Income$-38,540,000.00
Net Margins-372.81%

Miscellaneous

Market Cap$253.31 million
Next Earnings Date4/1/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.88 out of 5 stars

Medical Sector

1084th out of 1,965 stocks

Pharmaceutical Preparations Industry

500th out of 772 stocks

Analyst Opinion: 0.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$2.15
+0.05 (+2.38 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JAGX News and Ratings via Email

Sign-up to receive the latest news and ratings for JAGX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions

What stocks does MarketBeat like better than Jaguar Health?

Wall Street analysts have given Jaguar Health a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Jaguar Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Jaguar Health?

Jaguar Health saw a decrease in short interest in February. As of February 12th, there was short interest totaling 3,490,000 shares, a decrease of 41.3% from the January 28th total of 5,950,000 shares. Based on an average daily volume of 61,480,000 shares, the short-interest ratio is currently 0.1 days.
View Jaguar Health's Short Interest
.

When is Jaguar Health's next earnings date?

Jaguar Health is scheduled to release its next quarterly earnings announcement on Thursday, April 1st 2021.
View our earnings forecast for Jaguar Health
.

How were Jaguar Health's earnings last quarter?

Jaguar Health, Inc. (NASDAQ:JAGX) announced its earnings results on Sunday, November, 15th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.11) by $0.10. The biotechnology company earned $2.77 million during the quarter. Jaguar Health had a negative net margin of 372.81% and a negative trailing twelve-month return on equity of 659.73%.
View Jaguar Health's earnings history
.

How has Jaguar Health's stock price been impacted by COVID-19?

Jaguar Health's stock was trading at $0.45 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, JAGX stock has increased by 377.8% and is now trading at $2.15.
View which stocks have been most impacted by COVID-19
.

Who are Jaguar Health's key executives?

Jaguar Health's management team includes the following people:
  • Ms. Lisa A. Conte, Founder, CEO, Pres & Director (Age 62, Pay $515.23k)
  • Mr. Jonathan S. Wolin CPA, J.D., M.B.A., Chief of Staff, Chief Compliance Officer & Gen. Counsel (Age 59, Pay $293.06k)
  • Dr. Steven R. King, Chief Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec. (Age 63, Pay $323.67k)
  • Ms. Carol R. Lizak, Sr. VP of Fin. & Chief Accounting Officer (Age 57)
  • Dr. Pravin R. Chaturvedi Ph.D., Chair of Scientific Advisory Board & Acting Chief Scientific Officer (Age 58)
  • Mr. Peter Hodge, Sr. Director of Investor Relations, Bus. Devel. & Special Events
  • Mr. David Sesin, Chief Manufacturing Officer
  • Mr. Ian H. Wendt M.B.A., Chief Commercial Officer
  • Ms. Melissa A. Yeager J.D., Sr. VP of Regulatory Affairs & Quality Assurance (Age 67)
  • Dr. Michael K. Guy D.V.M., M.S., Ph.D., VP of Preclinical & Nonclinical Studies

Who are some of Jaguar Health's key competitors?

What other stocks do shareholders of Jaguar Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC), Sorrento Therapeutics (SRNE), Trevena (TRVN), Vaxart (VXRT), Purple Biotech (KTOV), Onconova Therapeutics (ONTX), Tonix Pharmaceuticals (TNXP), Biopharmx (BPMX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

When did Jaguar Health IPO?

(JAGX) raised $22 million in an IPO on Wednesday, May 13th 2015. The company issued 3,200,000 shares at a price of $7.00 per share. Aegis Capital Corp acted as the underwriter for the IPO and CRT Capital and Feltl and Company were co-managers.

What is Jaguar Health's stock symbol?

Jaguar Health trades on the NASDAQ under the ticker symbol "JAGX."

How do I buy shares of Jaguar Health?

Shares of JAGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jaguar Health's stock price today?

One share of JAGX stock can currently be purchased for approximately $2.15.

How much money does Jaguar Health make?

Jaguar Health has a market capitalization of $253.31 million and generates $5.78 million in revenue each year. The biotechnology company earns $-38,540,000.00 in net income (profit) each year or ($6.89) on an earnings per share basis.

How many employees does Jaguar Health have?

Jaguar Health employs 29 workers across the globe.

What is Jaguar Health's official website?

The official website for Jaguar Health is www.jaguaranimalhealth.com.

Where are Jaguar Health's headquarters?

Jaguar Health is headquartered at 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105.

How can I contact Jaguar Health?

Jaguar Health's mailing address is 201 MISSION STREET SUITE 2375, SAN FRANCISCO CA, 94105. The biotechnology company can be reached via phone at 415-371-8300.


This page was last updated on 3/1/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.